In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses clinical trial fail rates and AI’s potential to reduce preclinical costs with Mutlu Dogruel, VP of AI and Mark ...

President Donald Trump first threatened pharma tariffs in February and recently said they were imminent. Johnson & Johnson’s new investment adds to a $55 billion pledge made by the company in March.

Stealth BioTherapeutics originally submitted elamipretide for approval in January 2024, only to receive a rejection in May of this year. In addition to accepting the biotech’s resubmission, the FDA ...

In an open letter, Health and Human Services employees asked the Secretary to stop and disavow the spread of health misinformation, particularly about vaccines, infectious diseases and federal health ...

The delays, first revealed in Regeron’s Q2 report, were chalked up to manufacturing issues at Novo Nordisk-owned plants.

Looking for a biopharma job in Massachusetts? Check out the BioSpace list of nine companies hiring life sciences professionals like you.

VantAI will use its machine learning capabilities to identify novel target-effector pairs that Halda can use in designing its ...

Capricor Therapeutics met with the FDA last week for a type A meeting, during which CEO Linda Marbán aimed to explain to the ...

In late May, a patient died after receiving Rocket Pharmaceuticals' investigational gene therapy for Danon disease, spurring ...

The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new ...

With its structural changes, CSL expects to generate $500 to $550 million in annualized savings over the next three years.

Regulations aiming to lower the cost of vital medicines will instead end up restricting access and disincentivizing R&D.